Strongest evidence
Lactobacillus salivarius UCC118 shows the most consistent research support for reducing inflammation, with 8 of 8 studies (5 moderate, 3 small effect sizes) reporting beneficial effects, including one meta-analysis and one RCT. Moderate evidence also supports improvements in insulin sensitivity (6 of 6 studies, all moderate effects) and glucose metabolism (4 of 4 studies, moderate effects), primarily in pregnant women with gestational diabetes mellitus (GDM). Three meta-analyses further suggest a moderate reduction in GDM prevalence with probiotic supplementation, though these analyses included multiple strains, not exclusively UCC118.
Mixed or weaker evidence
For outcomes graded as low or very low evidence strength, findings are uniformly positive but rely heavily on review articles, animal studies, or in silico work, with few original human trials. For example, 6 studies report small beneficial effects on gut health, but none reached statistical significance. Similarly, 10 studies on gastrointestinal health all show benefit, yet all are review articles or case reports with no controlled human trials. Reduced insulin levels show conflicting results: 2 studies suggest benefit, but a high-quality RCT (n=149) found no effect. Other outcomes like immune modulation, infection risk, and gut microbiota modulation are based on small numbers of reviews and lack statistical significance.
Effective dose patterns
No consistent dose or form of Lactobacillus salivarius UCC118 emerged across the research syntheses. Doses were either not reported or varied widely, preventing any cross-cutting dose range recommendations.
Population insights
The strongest and most consistent evidence comes from studies in pregnant women, particularly those with gestational diabetes mellitus or overweight/obesity. Benefits for inflammation were observed in broader populations (multiple sclerosis, obesity, IBD, cancer patients), but the evidence base for insulin and glucose outcomes is largely limited to pregnancy.
Notable caveats
Across all outcomes, the research is subject to publication bias—null results are less likely to be published. Many studies are meta-analyses or reviews of mixed probiotic strains, not specific to UCC118. Only a few original randomized controlled trials with adequate sample sizes exist, and statistical significance was often not reported. The lack of consistent dosing, form, and study duration limits practical conclusions.